Book ChapterDOI
Neurochemical modulation of orbitofrontal cortex function
Trevor W. Robbins,Luke Clark,Hannah F. Clarke,Angela C. Roberts +3 more
- pp 393-422
Reads0
Chats0
About:
The article was published on 2006-10-12. It has received 9 citations till now. The article focuses on the topics: Orbitofrontal cortex & Neurochemical.read more
Citations
More filters
Journal ArticleDOI
Impulsivity as a vulnerability marker for substance-use disorders: Review of findings from high-risk research, problem gamblers and genetic association studies
TL;DR: The evidence that impulsivity is associated with addiction vulnerability is reviewed by considering three lines of evidence: studies of groups at high-risk for development of SUDs; studies of pathological gamblers, where the harmful consequences of the addiction on brain structure are minimised, and genetic association studies linking impulsivity to genetic risk factors for addiction.
Journal ArticleDOI
The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks.
TL;DR: There is clear neuropharmacological and neuroanatomical evidence that stop-signal and go/no-go tasks represent different forms of action inhibition, which translates with remarkable consistency across species.
Journal ArticleDOI
The orbitofrontal cortex: novelty, deviation from expectation, and memory.
TL;DR: Functional neuroimaging evidence is provided that there is a difference between the anterior and posterior orbitofrontal cortex in such processing of novel information, breaches of expectation, and memory.
Journal ArticleDOI
Behavioral outcomes of late-onset or early-onset orbital frontal cortex (areas 11/13) lesions in rhesus monkeys
TL;DR: In monkeys, self‐regulation abilities mediated by OFC areas 11/13 emerge from midinfancy through adolescence, and damage to these specific OFC subfields in adult monkeys resulted in profound changes in the flexible modulation of responses guided by reward value.
Journal ArticleDOI
The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.
TL;DR: A neuropharmacological account for hallucinatory experiences triggered by serotonin, and a drug to target sleep paralysis hallucinations and fear reactions, namely the selective 5-HT2AR inverse agonist, pimavanserin are proposed.